Iscom technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation
Lövgren Bengtsson K, Morein B, Osterhaus ADME.
Expert Rev. Vaccines 10(4), 401-403 (2011)
www.expert-reviews.com/toc/erv/10/4
A novel guinea pig model of Chlamydia trachomatis genital tract infection.
Marien I. de Jongea, Sander A.S. Keizera, Hicham M. el Moussaouia, Lieke van Dorstena, Rima Azzawia, Hanneke I. van Zuilekoma, Patricia P.W. Petersa, Fred J.H. van Opzeelandc, Laura van Dijka, Rob Nieuwlandb, Henriëtte W.M. Roosenboom-Theunissenb, Mieke P. Vrijenhoekb, Isolde Debyserd, Pierre J.M. Verweije, Wilbert G.F. van Duijnhovene, Johannes F. van den Boscha, Piet J.M. Nuijtena
Vaccine 29 (2011) 5994-6001
www.ncbi.nlm.nih.gov/pubmed/21718744
Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
Madhun AS, Haaheim LR, Nilsen MV, Cox RJ.
Vaccine, 2009 Dec 9;27(52):7367-76
www.ncbi.nlm.nih.gov/pubmed/19781678
Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ.
Influenza Other Respi Viruses. 2011 May 9. doi: 10.1111/j.1750-2659.2011.00256.x.
www.ncbi.nlm.nih.gov/pubmed/21668670
Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K, Rodriguez A, Mintardjo R, Tax D, Bengtsson KL, Thompson C, Zambon M, Weverling GJ, Uytdehaag F, Goudsmit J.
Vaccine, 2008 Jul 4;26(29-30):3640-6
www.ncbi.nlm.nih.gov/pubmed/18514980
Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells.
Yu H, Jiang X, Shen C, Karunakaran KP, Jiang J, Rosin NL, Brunham RC.
Infection and Immunity, 2010 May;78(5):2272-82
www.ncbi.nlm.nih.gov/pubmed/20231405
Vaccination of horses against strangles using recombinant antigens from Streptococcus equi.
Waller A, Flock M, Smith K, Robinson C, Mitchell Z, Karlström A, Lannergård J, Bergman R, Guss B, Flock JI.
Vaccine, 2007 May 4;25(18):3629-35
www.ncbi.nlm.nih.gov/pubmed/17321016
Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix.
Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ.
Vaccine, 2010 Oct 8;28(43):6989-96
www.ncbi.nlm.nih.gov/pubmed/20728523
The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.
Vaccine, 2009 Sep 4;27(40):5530-7
Heldens JG, Pouwels HG, Derks CG, Van de Zande SM, Hoeijmakers MJ.
www.ncbi.nlm.nih.gov/pubmed/19607950
Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypable Haemophilus influenzae-specific long-term mucosal immune responses in teh nasopharynx
Vaccine, 2011 Feb 24; 29(10):1881-90
Satoru Kodama, Takashi Hirano, Kenji Noda, Shingo Umemoto, Masashi Suzuki
www.ncbi.nlm.nih.gov/pubmed/21237276
Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants
Vaccine, 2009 Jul 16; 27(33):4439-46
J. Poot, L.H.M. Janssen, T.J. van Kasteren-Westerneng, K.H.A. van der Hekjden-Liefkens, V.E.J.C. Schijns, A. Heckeroth
www.ncbi.nlm.nih.gov/pubmed/19500553
Immune response to Neospora caninuim negative antigens formulated with immune stimulating complexes in calves
Vet. Parasitol, 2011 Feb 10;175(3-4):245-51
D.P. Moore, I.Echaide, A.E. Verna, M.R. Leunda, A. Cano, S. Pereyra, P.I. Zamorano, A.C. Odeón, C.M. Campero
www.ncbi.nlm.nih.gov/pubmed/21074325
|
|
|
|
|
|
|
|
|
|
|
|